Search - tctmd.com

Displaying 1 - 20 of 72

Sort: Relevancy | Date

News Daily News

FDA Panel Declines to Endorse Ventura Interatrial Shunt for HFrEF

Todd Neale

December 05, 2025

News Daily News

Donor Hearts Fare Better With Novel Method After Circulatory Death

Michael O'Riordan

May 01, 2025

News Conference News ACC 2025

By 2 Years, Tricuspid TEER Reduces Hospitalizations for HF: TRILUMINATE

Michael O'Riordan

March 31, 2025

News Daily News

Lower Risk of Mortality for Shock Patients Transferred to Expert Centers

Caitlin E. Cox

March 17, 2025

News Conference News CRT 2025

SMART: Small Aortic Annuli Still Fare Best With Self-Expandable Valves at 2 Years

L.A. McKeown

March 10, 2025

News Daily News

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Michael O'Riordan

January 22, 2025

News Conference News TCT 2024

TAVR UNLOAD: No Rush to Do TAVI in HFrEF Patients With Moderate AS

Todd Neale

October 28, 2024

News Daily News

Acute HF Patients Live Longer When Seen by Specialists

Michael O'Riordan

August 09, 2024

News Daily News

Reduced Vascular Load, Better RV Function With Dapagliflozin in HFpEF

Michael O'Riordan

July 26, 2024

News Daily News

The Hole Story: Interatrial Shunt Companies Are—Mostly—Pushing Ahead

Michael O'Riordan

June 20, 2024

News Conference News ESC Heart Failure 2024

Remote Monitoring in Real-world HF Cuts All-Cause Mortality: TELESAT-HF

Michael O'Riordan

May 12, 2024

News Daily News

SGLT2 Inhibitor Added to GDMT in Functional MR May Obviate Need for TEER

Michael O'Riordan

May 07, 2024

News Daily News

TAVI Outcomes Linked to LV Recovery in Patients With Severe Dysfunction

Michael O'Riordan

May 06, 2024

News Conference News ACC 2024

Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It

Michael O'Riordan

March 27, 2024

News Conference News THT 2024

Small Study Hints at Potential for HF Bone Marrow Cell Therapy: CardiAMP-HF

Michael O'Riordan

March 08, 2024

News Conference News THT 2024

Small Study Hints at Apixaban’s Potential in LVAD-Treated Patients

Michael O'Riordan

March 07, 2024

News Conference News THT 2024

Durable 1-Year Outcomes With Coronary Sinus Shunt for HF: ALT-FLOW EFS

Michael O'Riordan

March 06, 2024

News Conference News THT 2024

Debating the Role of T-TEER in the Sickest Patients

Michael O'Riordan

March 05, 2024

Dropping Aspirin Cuts Strokes, Bleeds, Hospital Stays in LVAD Patients: ARIES-HCM3

News Conference News AHA 2023

Dropping Aspirin Cuts Strokes, Bleeds, Hospital Stays in LVAD Patients: ARIES-HM3

Shelley Wood

November 11, 2023

News Conference News HFSA 2023

REBALANCE-HF Uncovers HFpEF Group That Responds to Splanchnic Nerve Ablation

Todd Neale

October 11, 2023

Advertisement

FDA Panel Declines to Endorse Ventura Interatrial Shunt for HFrEF

Donor Hearts Fare Better With Novel Method After Circulatory Death

By 2 Years, Tricuspid TEER Reduces Hospitalizations for HF: TRILUMINATE

Lower Risk of Mortality for Shock Patients Transferred to Expert Centers

SMART: Small Aortic Annuli Still Fare Best With Self-Expandable Valves at 2 Years

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

TAVR UNLOAD: No Rush to Do TAVI in HFrEF Patients With Moderate AS

Acute HF Patients Live Longer When Seen by Specialists

Reduced Vascular Load, Better RV Function With Dapagliflozin in HFpEF

The Hole Story: Interatrial Shunt Companies Are—Mostly—Pushing Ahead

Remote Monitoring in Real-world HF Cuts All-Cause Mortality: TELESAT-HF

SGLT2 Inhibitor Added to GDMT in Functional MR May Obviate Need for TEER

TAVI Outcomes Linked to LV Recovery in Patients With Severe Dysfunction

Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It

Small Study Hints at Potential for HF Bone Marrow Cell Therapy: CardiAMP-HF

Small Study Hints at Apixaban’s Potential in LVAD-Treated Patients

Durable 1-Year Outcomes With Coronary Sinus Shunt for HF: ALT-FLOW EFS

Debating the Role of T-TEER in the Sickest Patients

Dropping Aspirin Cuts Strokes, Bleeds, Hospital Stays in LVAD Patients: ARIES-HM3

REBALANCE-HF Uncovers HFpEF Group That Responds to Splanchnic Nerve Ablation

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content